KYVERNA THERAPEUTICS
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
KYVERNA THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2018-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.kyvernatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
110 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - Kyverna Therapeutics
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series B - Kyverna Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series B - Kyverna Therapeutics
Vida Ventures
Vida Ventures investment in Series B - Kyverna Therapeutics
The Argentum Group
The Argentum Group investment in Series B - Kyverna Therapeutics
Gilead Sciences
Gilead Sciences investment in Series B - Kyverna Therapeutics
CAM Capital
CAM Capital investment in Series B - Kyverna Therapeutics
Insight Partners
Insight Partners investment in Series B - Kyverna Therapeutics
LYFE Capital
LYFE Capital investment in Series B - Kyverna Therapeutics
Intellia Therapeutics
Intellia Therapeutics investment in Series B - Kyverna Therapeutics
Key Employee Changes
Official Site Inspections
http://www.kyvernatx.com Semrush global rank: 7.27 M Semrush visits lastest month: 548
- Host name: 37.120.75.34.bc.googleusercontent.com
- IP address: 34.75.120.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kyverna Therapeutics"
Mission & Values | Kyverna
The Bedrock of Our Organization. Bring Intellectual Rigor. We ask thoughtful questions to respectfully advance breakthrough innovations, guide decision-making and deliver …See details»
Career Opportunities in Autoimmune Research | Kyverna
We are actively building a top-notch scientific organization comprised of industry and domain experts to position Kyverna as a fully integrated organization with the breadth of capabilities to discover, develop and commercialize our own …See details»
Kyverna Therapeutics - Crunchbase Company Profile
Contact Email [email protected] KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic …See details»
Kyverna Therapeutics - LinkedIn
Kyverna Therapeutics | 17,274 followers on LinkedIn. Harnessing the power of cell therapy in autoimmune disease. | Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused ...See details»
Kyverna Therapeutics Announces Leadership Update
Sep 16, 2024 "Since its inception in 2018, Kyverna has made tremendous progress in pursuit of a paradigm shift for patients with autoimmune disease. Kyverna today sits on the precipice of …See details»
Kyverna Therapeutics Appoints Mert Aktar to its Board …
Oct 21, 2024 Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today ...See details»
Kyverna Therapeutics Provides Business Update and Reports Full …
Dec 31, 2023 Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited …See details»
Kyverna is a Clinical-Stage Biopharmaceutical Company …
Discover Kyverna, a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.See details»
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Oct 21, 2024 "We are delighted to welcome Mert to Kyverna's Board of Directors as we continue to advance KYV-101 into later stages of development and build on Kyverna's CAR T …See details»
Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND …
Nov 13, 2023 For more information, please visit https://kyvernatx.com. Kyverna Media Contact: Katie Dodge +1 (978) 360-3151 [email protected] 1. Brudno et al., Nature Medicine 2020; …See details»
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board …
Sep 15, 2021 Prior to Roche/Genentech, she was Vice President of Global Quality at Seagen Inc., formerly Seattle Genetics, Inc., where she oversaw and directed the Global Quality …See details»
Kyverna Therapeutics Provides Business Update and Reports …
Aug 12, 2024 Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from …See details»
Kyverna Therapeutics Secures $25 Million Series A Funding from …
Jan 13, 2020 As part of this financing, Fred Cohen, M.D., D.Phil., Co-Founder and Senior Managing Director of Vida Ventures will serve as Chairman of the Board. Beth Seidenberg, M ...See details»
Karen Walker - Kyverna Therapeutics
Karen Walker is Chief Technology Officer at Kyverna Therapeutics. Ms. Walker has broad and deep industry experience developing biopharmaceuticals and cell and gene therapy (CGT) …See details»
Kyverna’s KYV-101 Receives U.S. FDA Clearance ... - Kyverna …
For more information, please visit https://kyvernatx.com. Kyverna Media Contact: Consort Partners for Kyverna [email protected]. 1 Walton C, et al. Mult Scler. 2020; 26: …See details»
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board …
Sep 15, 2021 EMERYVILLE, Calif., September 15, 2021 – Kyverna Therapeutics, Inc., a cell therapy company focused on engineering a new class of therapies for serious autoimmune …See details»
Recommended Stories - Yahoo Finance
Jan 3, 2024 Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from …See details»
Kyverna Therapeutics Closes $85 Million Series B Financing led by ...
EMERYVILLE, Calif., Jan. 26, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, …See details»